International Journal of Arts and Social Science www.ijassjournal.com
ISSN: 2581-7922,
Volume 8 Issue 10, October 2025

Evolution of Papanicolaou's Smear: Actor – Network Theory Perspective

Ghada Al-Najar[1& 2], Avinash Kundur[1], Indu Singh[1]

[1.]*School of Pharmacy and Medical Sciences, Building G05-2.13 Parklands Drive, Southport, QLD, 4222 Australia.*
[2.]*Cytology Scientist at Sullivan Nicolaides Pathology, 24 Hurworth Street, Bowen Hills, QLD 4006 Australia PO Box 2014 Fortitude Valley, QLD 4006 Australia*

ABSTRACT: The Papanicolaou smear (Pap smear) represents a landmark innovation in public health, emerging from a complex network of human and non-human actors. Through the lens of Actor–Network Theory, the development of the cervical screening test can be understood as the result of dynamic interactions among scientific, social, and technological elements including Dr. George N. Papanicolaou, laboratory instruments, and volunteer participants.This paper traces the evolution of self-collection methods for vaginal fluid samples, illustrating how innovation was co-produced through collaboration across diverse actors. The widespread adoption of the Pap smear highlights the interplay between science, policy, and public engagement in shaping the trajectory of preventive medicine.

KEYWORDS: Actor–Network Theory, Papanicolaou smear, self-collection, Human Papillomavirus, Inequity.

I. INTRODUCTION CERVICAL CANCER – A GLOBAL HEALTH INEQUITY

Cervical cancer **exemplified** a profound global health inequity, with outcomes **shaped** by unequal access to knowledge, healthcare services, and the broader cultural and social factors influencing disease prevention and care [1]. The development and dissemination of the Papanicolaou smear (Pap smear) illustrated how medical innovations emerged through complex interactions among human and non-human actors, ultimately forming the foundation of a preventive approach to cervical cancer [2]. Using Actor–Network Theory, this paper explores how the Pap smear stabilized as a routine screening tool through the coordination of scientists, instruments, policies, and patients [3].

Recent shifts toward self-collection of vaginal samples for Human Papillomavirus testing represent a significant transformation in screening practices, redistributing agency and accessibility [4-6]. Persistent high-risk Human Papillomavirus infection with oncogenic virus acts as a non-human agent within this assemblage, mobilizing the screening network and justifying continuous surveillance and follow-up [7, 8].

Yet, as Actor-Network Theory reminds us, risk was distributed across the network, encompassing biological, social, and behavioral factors [9]. The screening test therefore functioned as both a technical and social actor, maintaining network stability through the continual interaction of individuals, laboratories, technologies, and

policies. Over the past century, this evolving story has traced Papanicolaou's early cytological observations to organized screening programs and, more recently, to global cervical cancer elimination efforts [10].

II. VAGINAL FLUID SMEAR METHOD

At the heart of the evolution of cervical screening is the pioneering work of Dr. George N. Papanicolaou, whose research at Cornell Medical College laid the foundation for modern cervical cancer screening [11]. His initial work focused on reproductive biology and chromosomal mechanisms influencing sex determination and control in guinea pigs, using the vaginal fluid smear method [12]. Papanicolaou's early career at Cornell marked a significant step in his journey toward becoming a pioneer in cytopathology [13]. His work with Dr. Charles S. Stockard focused on reproductive physiology, specifically developing methods to identify ovulation in guinea pigs [14]. Working alongside Dr. Stockard, Papanicolaou studied how environmental factors, such as ethanol exposure, influenced chromosomal changes and reproductive health [15].

These early studies provided the scientific basis for cytological screening, culminating in the vaginal fluid smear method, one of the most effective cervical cancer screening tools ever developed. The groundbreaking research of Papanicolaou and Stockard was first published in Science in 1915 under the title Sex Determination and Sex Control in Guinea Pigs [16]. His work not only deepened understanding of reproductive physiology in guinea pigs but also laid the foundation for applying cytological methods to human reproductive health and disease, ultimately leading to the creation of the Papanicolaou's smear for early detection of cervical cancer [15, 17].

III. ACTOR–NETWORK THEORY PERSPECTIVE ON THE SMEAR METHOD

A significant milestone in the evolution of cervical cancer prevention was Dr. Papanicolaou's development of the vaginal fluid smear method, a breakthrough that transformed both reproductive biology and diagnostic cytology[11]. Viewed through the lens of Actor–Network Theory, this innovation was not the product of isolated genius, but the result of a networked assemblage of actors: Papanicolaou himself, laboratory instruments (such as microscopes and staining tools), experimental guinea pigs, epithelial cells, and the physiological rhythms of the oestrous cycle [18]. By using this technique to identify and characterize the four stages of the oestrous cycle each marked by distinct nuclear and cytoplasmic features these human and non-human actors collectively generated new forms of knowledge [9].

The epithelial cells became inscription devices, materials that could be made to speak within the lab setting, while the staining methods and interpretive frameworks functioned as mediators translating biology into readable data. Within this network, the smear method gained credibility, allowing it to evolve into the Pap smear and extend its reach beyond the lab into clinical and public health domains [3, 19].

The development of cervical cytology, particularly the Papanicolaou's smear, stands as one of the most transformative achievements in public health [20]. Emerging in the early twentieth century, this innovation revolutionized cancer screening by enabling detection of precancerous changes long before symptoms appeared [21]. The pioneering work of Dr. George N. Papanicolaou, supported by Mrs. Andromache Papanicolaou, who allowed him to collect cervical cell samples over many years [22], led to a test that has saved millions of lives through organized screening programs worldwide, highlighted next [23].

IV. SELF-COLLECTION OF VAGINAL FLUID SAMPLES

Papanicolaou considered whether a similar methodology could facilitate studies of the hormonal cycle in women [12, 24, 25]. A key challenge was the requirement for repetitive, daily sampling of vaginal fluid a hard yet essential

component of the research process. In 1920, Papanicolaou's wife, Andromache, supported his investigations by consenting to daily sample collection over a period of twenty-one years [26]. Her contributions were pivotal to the refinement of the Pap smear and the subsequent establishment of the cytomorphological characteristics of normal gynecological cells [27]. The study served as a benchmark for identifying normal cellular patterns for diagnostic purposes. Papanicolaou's meticulous approach involved collecting vaginal fluid samples, smearing them onto microscope slides, and staining them a technique that remained widely employed in anatomical pathology as the Papanicolaou stain [28].

From an Actor-Network Theory perspective, the development of the Papanicolaou test illustrates how scientific innovation emerges through a network of human and non-human actors [29]. Within this network, Andromache functioned as a crucial human actor contributing not only biological samples but also emotional and relational support, while non-human actors such as microscopes, reagents, and slides played vital roles in stabilizing the network and enabling reproducibility [30].

The first documented reference to self-collection by women appeared in 1933 [28], when Papanicolaou correlated cytological findings from vaginal epithelial cells with ovarian and uterine physiology. He initially examined samples from twelve hospital employees, later expanding his studies to include surgical and pregnant patients, and published preliminary findings in 1925 [28]. This iterative approach was refined over time and was formally recognized as the Pap smear test by the American Cancer Society in 1948 [31].

Papanicolaou and Shorr described self-collection techniques in 1936 within endocrinological studies [20], and the method was referenced again in the 1943 monograph by Papanicolaou and Traut [32]. The test's clinical utility was consolidated through the American Cancer Society's endorsement in 1948 and was validated by the Memphis–Shelby County clinical trial (1951–1957), which confirmed its efficacy [33].

The emergence of the Papanicolaou test exemplified a core principle of Actor-Network Theory: discovery was not the outcome of isolated genius but the product of dynamic, heterogeneous interactions linking people, technologies, institutions, bodies, and values [34]. In this actor-network, Andromache's role extended beyond that of a technical assistant; she became one of the first consistent human subjects, donating numerous vaginal smears and thereby helping to stabilize and validate the method [35]. See Figure 1.1 Pyramid of Papanicolaou Smear Test Network: Illustrating the network of human and non-human actors stabilizing the Pap smear, including Papanicolaou, Andromache, laboratory instruments, epithelial cells, institutional support, and clinical application.

V. CONCLUSION

Papanicolaou refined the understanding of epithelial cytomorphology through a research approach that required repeated sampling of vaginal fluid to enable daily comparisons of epithelial cells. This meticulous method reflected the experimental rigor and scientific curiosity characteristic of early 20th-century medicine. His efforts laid the groundwork for the development and optimization of the Pap smear, which became integrated into population-based gynaecological healthcare by 1948.

The vaginal fluid smear method exemplifies the principles of Actor–Network Theory, as the Pap smear was mobilized within a network of translations that gradually stabilized over time. Although the technique initially faced resistance, alliances with endocrinology, the American Cancer Society, and clinical research trials facilitated its widespread adoption. The Pap smear thus illustrates how a socio-technical network composed of human and non-human actors was constructed, disrupted, and reconfigured into a globally institutionalized practice of cervical cancer prevention.



Figure 1.1 Pyramid of Papanicolaou Smear Test Network.

Acknowledgements: The corresponding author:

Ghada Al-Najar is particularly grateful to Dr Nicholas Chantziantoniou, for his invaluable support, thank you.

REFERENCES

[1] Ruzindana, K. and R.I. Anorlu, *Global disparities in gynecologic cancer outcomes: a call for action.* International Journal of Gynecology & Obstetrics, 2025. **171**: p. 210-220.
[2] Casper, M.J. and A.E. Clarke, *Making the Pap smear into theRight Tool'for the job: cervical cancer screening in the USA, circa 1940-95.* Social studies of science, 1998. **28**(2): p. 255-290.
[3] Singleton, V. and M. Michael, *Actor-networks and ambivalence: General practitioners in the UK cervical screening programme.* Social studies of science, 1993. **23**(2): p. 227-264.
[4] Gomes, M., et al., *Improving Accessibility of Cervical Cancer Screening: A Global Perspective on Self-Sampling and Digital Innovation.* 2024.
[5] Daponte, N., et al., *HPV-based self-sampling in cervical cancer screening: an updated review of the current evidence in the literature.* Cancers, 2023. **15**(6): p. 1669.

[6] Camara, H., et al., *Self-collection for HPV-based cervical screening: a qualitative evidence meta-synthesis.* BMC Public Health, 2021. **21**(1): p. 1503.
[7] van Eer, K., *The human papillomavirus: Dynamics between vaccination, viral properties and surveillance.* 2025.
[8] Galati, L., et al., *Human oncogenic viruses: characteristics and prevention Strategies—Lessons learned from human papillomaviruses.* Viruses, 2024. **16**(3): p. 416.
[9] Jette, S., *Studying humans and non-humans in risk governance: how actor-network theory can help us do 'non-modern' research.* Qualitative Research in Sport, Exercise and Health, 2025: p. 1-16.
[10] Swanson, A.A. and L. Pantanowitz, *The evolution of cervical cancer screening.* Journal of the American Society of Cytopathology, 2024. **13**(1): p. 10-15.
[11] Avdulla, C.S. and N. Tachirai, *George N. Papanicolaou (1883–1962): The Pioneer of Cytology and Early Cancer Detection.* Cureus, 2024. **16**(9).
[12] Papanicolaou, G.N., *A general survey of the vaginal smear and its use in research and diagnosis.* American journal of obstetrics and gynecology, 1946. **51**(3): p. 316-328.
[13] Austin, R.M. and N. Chantziantoniou, *George Nicholas Papanicolaou: the unlikely story of an intellectual immigrant; one driven to contribute on a large stage; one who finally succeeded by scientifically inspiring numerous cooperating individuals and organizations.* Journal of the American Society of Cytopathology, 2014. **3**(6): p. 331-334.
[14] Stockard, C.R. and G.N. Papanicolaou, *The vaginal closure membrane, copulation, and the vaginal plug in the guinea-pig, with further considerations of the oestrous rhythm.* The Biological Bulletin, 1919. **37**(4): p. 222-245.
[15] Sawin, C.T., *George N. Papanicolaou and the "Pap" Test.* The Endocrinologist, 2002. **12**(4): p. 267-272.
[16] Papanicolaou, G., *Sex determination and sex control in guinea-pigs.* Science, 1915. **41**(1054): p. 401-404.
[17] Manglik, M.R., *Essentials of Gynecologic Cytology*. 2024: EduGorilla Publication.
[18] Edwards, S., *Doing actor-network theory: integrating network analysis with empirical philosophy in the study of research into genetically modified organisms in New Zealand*. 2014, Lincoln University.
[19] Clarke, A.E. and M.J. Casper, *From simple technology to complex arena: Classification of Pap smears, 1917–90.* Medical anthropology quarterly, 1996. **10**(4): p. 601-623.
[20] Swailes, A.L., C.E. Hossler, and J.P. Kesterson, *Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day.* Gynecologic oncology, 2019. **154**(1): p. 3-7.
[21] Nikoloudi, M. and K. Mystakidou, *Dr. George Papanicolaou: The Visionary Who Revolutionized Women's Health.* Cureus, 2024. **16**(9).
[22] Chantziantoniou, N., *The Pap test-Celebrating 100 years in the making and beyond.* Journal of the American Society of Cytopathology, 2013. **3**(3): p. 143-150.
[23] Chantziantoniou, N., *Impediments to the historical development of the clinical Pap test in the United States: their relevance in optimizing cervical cancer screening in the State of Qatar.* 2019.
[24] Papanicolaou, G.N., *The sexual cycle in the human female as revealed by vaginal smears.* American Journal of Anatomy, 1933. **52**(S1): p. 519-637.
[25] Michalas, S.P., *The Pap test: George N. Papanicolaou (1883–1962): a screening test for the prevention of cancer of uterine cervix.* European Journal of Obstetrics & Gynecology and Reproductive Biology, 2000. **90**(2): p. 135-138.

[26] Chantziantoniou, N., *Lady Andromache (Mary) Papanicolaou: the soul of gynecological cytopathology.* Journal of the American Society of Cytopathology, 2014. **3**(6): p. 319-326.
[27] Elgert, P.A. and N. Chantziantoniou, *Biography of George N. Papanicolaou, MD, PhD: historical variations of the reported wedding date.* Acta Cytologica, 2023. **67**(1): p. 102-104.
[28] Chantziantoniou, N., et al., *Inception and development of the papanicolaou stain method.* Acta cytologica, 2017. **61**(4-5): p. 266-280.
[29] Chantziantoniou, N., *The Kymi odyssey honorary ceremony and the future GN papanicolaou museum: a personal appeal for support, enrichment, and visitation.* Acta cytologica, 2024. **68**(1): p. 6-12.
[30] MacLeod, A., et al., *Actor-network theory and ethnography: Sociomaterial approaches to researching medical education.* Perspectives on medical education, 2019. **8**(3): p. 177-186.
[31] Waxman, A.G., *Guidelines for Cervical Cancer Screening: History and Scientific Rationale.* Clinical Obstetrics and Gynecology, 2005. **48**(1): p. 77-97.
[32] John G. Kidd, M.D., *George N. Papanicolaou 1883–1962* American Journal of Clinical Pathology, 1963. **Volume 39**(Issue 4): p. 400–405.
[33] Castle, P.E., *Looking back, moving forward: challenges and opportunities for global cervical cancer prevention and control.* Viruses, 2024. **16**(9): p. 1357.
[34] Michael, M., *Actor-network theory: Trials, trails and translations.* 2016.
[35] Hajdu, S.I., *Pathfinders in oncology from the beginning of modern surgery of intracranial tumors to the introduction of the Pap smear.* Cancer, 2020. **126**(12): p. 2734-2749.